Management of ventricular arrhythmias

Area of Science:

• Cardiology
• Electrophysiology
• Pharmacology

Background:

• Left ventricular dysfunction and complex ventricular premature contractions (VPCs) are significant independent risk factors for cardiac death in patients with ischemic or nonischemic heart disease.
• The management of arrhythmias, particularly during acute myocardial infarction, requires careful consideration of antiarrhythmic drug therapy.

Purpose of the Study:

• To discuss the appropriate use of antiarrhythmic drugs in patients with heart disease and complex VPCs.
• To outline methods for evaluating antiarrhythmic drug efficacy and guiding treatment selection for ventricular tachyarrhythmias.

Main Methods:

• Evaluation of antiarrhythmic drug efficacy through 24-hour ambulatory ECG monitoring and treadmill exercise stress testing.
• Measurement of blood drug levels to ensure therapeutic concentrations.
• Electrophysiologic testing (EP) with programmed ventricular stimulation to predict clinical efficacy for long-term management of ventricular tachyarrhythmias.

Main Results:

• Patients with complex VPCs associated with heart disease should receive antiarrhythmic drug treatment.
• EP testing is crucial for selecting antiarrhythmic drugs in patients with a history of sustained ventricular tachycardia or ventricular fibrillation, even if currently asymptomatic on monitoring.
• Surgical intervention is indicated for life-threatening ventricular tachycardia or fibrillation resistant to antiarrhythmic drugs.

Conclusions:

• Antiarrhythmic drug therapy is indicated for complex VPCs in patients with heart disease, with efficacy guided by objective testing.
• Electrophysiologic testing plays a vital role in tailoring antiarrhythmic drug selection for refractory ventricular arrhythmias.
• Complex VPCs in asymptomatic individuals without underlying heart disease do not warrant antiarrhythmic drug treatment.